Societal value of lecanemab in Japan published in Neurology and Therapy
BioArctic AB’s partner Eisai announced the publication of results from a simulation study evaluating the societal value of lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer’s disease, in the context of the Japanese health care system in the peer-reviewed journal Neurology and Therapy.
Societal value of lecanemab in Japan published in Neurology and Therapy Read More »
